These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
451 related articles for article (PubMed ID: 32669376)
1. A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with Sullivan RJ; Weber J; Patel S; Dummer R; Carlino MS; Tan DSW; Lebbé C; Siena S; Elez E; Wollenberg L; Pickard MD; Sandor V; Ascierto PA Clin Cancer Res; 2020 Oct; 26(19):5102-5112. PubMed ID: 32669376 [TBL] [Abstract][Full Text] [Related]
2. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941 [TBL] [Abstract][Full Text] [Related]
3. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628 [TBL] [Abstract][Full Text] [Related]
4. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754 [TBL] [Abstract][Full Text] [Related]
5. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198 [No Abstract] [Full Text] [Related]
6. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. Schadendorf D; Dummer R; Flaherty KT; Robert C; Arance A; de Groot JWB; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Yamazaki N; Queirolo P; Guenzel C; Polli A; Thakur M; di Pietro A; Ascierto PA Eur J Cancer; 2024 Jun; 204():114073. PubMed ID: 38723373 [TBL] [Abstract][Full Text] [Related]
7. An overview of binimetinib for the treatment of melanoma. Specenier P Expert Opin Pharmacother; 2020 May; 21(7):747-754. PubMed ID: 32100585 [TBL] [Abstract][Full Text] [Related]
8. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). Gogas H; Dummer R; Ascierto PA; Arance A; Mandalà M; Liszkay G; Garbe C; Schadendorf D; Krajsová I; Gutzmer R; Sileni VC; Dutriaux C; Yamazaki N; Loquai C; Queirolo P; Jan de Willem G; Sellier AT; Suissa J; Murris J; Gollerkeri A; Robert C; Flaherty KT Eur J Cancer; 2021 Jul; 152():116-128. PubMed ID: 34091420 [TBL] [Abstract][Full Text] [Related]
9. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. Holbrook K; Lutzky J; Davies MA; Davis JM; Glitza IC; Amaria RN; Diab A; Patel SP; Amin A; Tawbi H Cancer; 2020 Feb; 126(3):523-530. PubMed ID: 31658370 [TBL] [Abstract][Full Text] [Related]
10. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705 [TBL] [Abstract][Full Text] [Related]
11. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussain M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE J Clin Oncol; 2023 Jul; 41(21):3700-3711. PubMed ID: 37270692 [TBL] [Abstract][Full Text] [Related]
12. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. Graf NP; Koelblinger P; Galliker N; Conrad S; Barysch M; Mangana J; Dummer R; Cheng PF; Goldinger SM J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):686-692. PubMed ID: 30468696 [TBL] [Abstract][Full Text] [Related]
13. Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib. Amagai R; Fujimura T; Kambayashi Y; Sato Y; Tanita K; Ohuchi K; Hashimoto A; Aiba S J Dermatol; 2020 Jun; 47(6):654-657. PubMed ID: 32293049 [TBL] [Abstract][Full Text] [Related]
15. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations. Trojaniello C; Festino L; Vanella V; Ascierto PA Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516 [TBL] [Abstract][Full Text] [Related]
16. A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer. Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussein M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE Future Oncol; 2024; 20(16):1047-1055. PubMed ID: 38357801 [TBL] [Abstract][Full Text] [Related]
17. Encorafenib plus binimetinib in patients with Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients. Indini A; Mandalà M Expert Opin Drug Saf; 2020 Oct; 19(10):1229-1236. PubMed ID: 32857940 [TBL] [Abstract][Full Text] [Related]
19. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic van Geel RMJM; Tabernero J; Elez E; Bendell JC; Spreafico A; Schuler M; Yoshino T; Delord JP; Yamada Y; Lolkema MP; Faris JE; Eskens FALM; Sharma S; Yaeger R; Lenz HJ; Wainberg ZA; Avsar E; Chatterjee A; Jaeger S; Tan E; Maharry K; Demuth T; Schellens JHM Cancer Discov; 2017 Jun; 7(6):610-619. PubMed ID: 28363909 [TBL] [Abstract][Full Text] [Related]
20. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma. Rose AAN Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]